These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38389126)

  • 61. Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells.
    Nishikawa R; Osaki M; Sasaki R; Ishikawa M; Yumioka T; Yamaguchi N; Iwamoto H; Honda M; Kabuta T; Takenaka A; Okada F
    Oncol Rep; 2020 Nov; 44(5):1810-1820. PubMed ID: 32901843
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP.
    Shen X; Sun X; Sun B; Li T; Wu G; Li Y; Chen L; Liu Q; Cui M; Zhou Z
    FEBS Lett; 2018 Feb; 592(4):599-609. PubMed ID: 29364502
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Upregulation of serine metabolism enzyme PSAT1 predicts poor prognosis and promotes proliferation, metastasis and drug resistance of clear cell renal cell carcinoma.
    Ye J; Huang X; Tian S; Wang J; Wang H; Feng H; Zhao X; Cao S; Xuan Y; Li X; Ma X; Huang Y; Zhang X
    Exp Cell Res; 2024 Apr; 437(1):113977. PubMed ID: 38373588
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The α-Arrestin ARRDC3 Is an Emerging Multifunctional Adaptor Protein in Cancer.
    Wedegaertner H; Pan WA; Gonzalez CC; Gonzalez DJ; Trejo J
    Antioxid Redox Signal; 2022 May; 36(13-15):1066-1079. PubMed ID: 34465145
    [No Abstract]   [Full Text] [Related]  

  • 65. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma.
    Paccez JD; Duncan K; Vava A; Correa RG; Libermann TA; Parker MI; Zerbini LF
    Mol Biol Cell; 2015 Mar; 26(5):821-31. PubMed ID: 25568334
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sunitinib-suppressed miR-452-5p facilitates renal cancer cell invasion and metastasis through modulating SMAD4/SMAD7 signals.
    Zhai W; Li S; Zhang J; Chen Y; Ma J; Kong W; Gong D; Zheng J; Xue W; Xu Y
    Mol Cancer; 2018 Nov; 17(1):157. PubMed ID: 30419914
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
    Liu W; Ren D; Xiong W; Jin X; Zhu L
    J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
    Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
    Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
    Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
    Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation.
    Li Y; Shen Y; Zhu Z; Wen H; Feng C
    Cancer Med; 2020 Aug; 9(16):6020-6029. PubMed ID: 32628820
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
    Kammerer-Jacquet SF; Brunot A; Lefort M; Bayat S; Peyronnet B; Verhoest G; Mathieu R; Lespagnol A; Mosser J; Laguerre B; Ravaud A; Bernhard JC; Dupuis F; Yacoub M; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Clin Genitourin Cancer; 2019 Jun; 17(3):169-176.e1. PubMed ID: 30837208
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
    Pan Y; Lu X; Shu G; Cen J; Lu J; Zhou M; Huang K; Dong J; Li J; Lin H; Song H; Xu Q; Han H; Chen Z; Chen W; Luo J; Wei J; Zhang J
    Cancer Res; 2023 Jan; 83(1):103-116. PubMed ID: 36264173
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
    Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
    Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
    Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
    PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
    Terry S; Dalban C; Rioux-Leclercq N; Adam J; Meylan M; Buart S; Bougoüin A; Lespagnol A; Dugay F; Moreno IC; Lacroix G; Lorens JB; Gausdal G; Fridman WH; Mami-Chouaib F; Chaput N; Beuselinck B; Chabaud S; Barros-Monteiro J; Vano Y; Escudier B; Sautès-Fridman C; Albiges L; Chouaib S
    Clin Cancer Res; 2021 Dec; 27(24):6749-6760. PubMed ID: 34407968
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.
    Niu ZS; Niu XJ; Wang WH
    Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
    Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
    Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
    [TBL] [Abstract][Full Text] [Related]  

  • 79. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization.
    Batur T; Argundogan A; Keles U; Mutlu Z; Alotaibi H; Senturk S; Ozturk M
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948046
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.